1
|
Zhao HG, Liu F, Qin TJ, Bai H, Hou M, Yu K, Hu Y, Liu L, Li Y, Yu L. [Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:811-817. [PMID: 33190437 PMCID: PMC7656073 DOI: 10.3760/cma.j.issn.0253-2727.2020.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Indexed: 11/29/2022]
Abstract
Objective: To evaluate the efficacy, safety, and pharmacokinetics of the generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes(MDS). Methods: Between October 2013 and 2016, 72 patients were eligible for enrollment at 9 sites from China received generic subcutaneous azacitidine 75 mg·m(-2)·d(-1) for 7 days per 28-day cycle, for ≥6 cycles. Pharmacokinetic blood samples were collected on day 1 of a single-dose. Results: For each patient at cycle 6 or at the time of study discontinuation, whichever came first, the overall response rate, which included complete remission (CR)and partial remission(PR), was 6.9%(5/72), the rate of patients who had the best effect with CR or PR during the treatment was 12.5%(9/72). Patients who were dependent on red-blood-cell transfusions and platelet transfusions at baseline became transfusion independent were 46.3%(19/41)and 41.2% (7/17), respectively. The median time of treatment was 6 cycles, and the median OS was 16.1 months (95%CI 10.9-20.6 months). For 36 patients(50%)received treatment at ≥6 cycles, and the median OS was 22.3 months(95%CI 16.1- not evaluative). Most common grade Ⅲ-Ⅳ hematologic treatment-emergent adverse events were neutropenia(55%), leukopenia(47%), and thrombocytopenia(61%). Pharmacokinetic profiles were similar for generic and original azacitidine in Chinese patients. Conclusion: Generic azacitidine treatment was favorable and safe and can be used as a standard treatment for patients with higher-risk MDS.
Collapse
Affiliation(s)
- H G Zhao
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
| | - F Liu
- Department of Hematology, Xiyuan Hospital, Chinese Academy of Medical Sciences, Beijing 100091, China
| | - T J Qin
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Bai
- Department of Hematology, Chinese People's Liberation Army Joint Logistics Support Unit 940 Hospital, Lanzhou 730050, China
| | - M Hou
- Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - K Yu
- Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Y Hu
- Department of Hematology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China
| | - L Liu
- Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China
| | - Y Li
- Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China
| | - L Yu
- Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China; Department of Hematology-Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen 518060, China
| |
Collapse
|